MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups Mohammed A. AleskandaranyEmad A. RakhaAndrew R. Green Preclinical study 11 July 2010 Pages: 591 - 599
Gene expression analysis reveals a different transcriptomic landscape in female and male breast cancer Maurizio CallariVera CappellettiMaria Grazia Daidone Preclinical study 13 July 2010 Pages: 601 - 610
Ionizing radiation or mitomycin-induced micronuclei in lymphocytes of BRCA1 or BRCA2 mutation carriers Sara Gutiérrez-EnríquezTeresa Ramón y CajalOrland Diez Preclinical study 13 July 2010 Pages: 611 - 622
Elevated TRF2 in advanced breast cancers with short telomeres Malissa C. DiehlMichael O. IdowuLynne W. Elmore Preclinical study 13 July 2010 Pages: 623 - 630
Native MAG-1 antibody almost destroys human breast cancer xenografts William G. NorthRoy H. L. PangBernard F. Cole Preclinical study 13 July 2010 Pages: 631 - 637
Microcephalin is a new novel prognostic indicator in breast cancer associated with BRCA1 inactivation Julie RichardsonAbeer M. ShaabanSandra M. Bell Preclinical study 15 July 2010 Pages: 639 - 648
Overexpression of the urokinase receptor mRNA splice variant uPAR-del4/5 affects tumor-associated processes of breast cancer cells in vitro and in vivo Sumito SatoCharlotte KopitzViktor Magdolen Preclinical study 16 July 2010 Pages: 649 - 657
GRB7 protein over-expression and clinical outcome in breast cancer Betsy RamseyTao BaiShiuh-Wen Luoh Preclinical study 16 July 2010 Pages: 659 - 669
International distribution and age estimation of the Portuguese BRCA2 c.156_157insAlu founder mutation Ana PeixotoCatarina SantosManuel R. Teixeira Preclinical study 22 July 2010 Pages: 671 - 679
Women’s interest in taking tamoxifen and raloxifene for breast cancer prevention: response to a tailored decision aid Angela FagerlinAmanda J. DillardPeter A. Ubel Clinical trial 26 March 2011 Pages: 681 - 688
A phase I clinical and pharmacological study evaluating vinflunine in combination with doxorubicin as first line treatment in metastatic breast cancer K. ZamanX. DurandoJ. Bauer Clinical trial 26 March 2011 Pages: 689 - 696
Change in blood flow velocity demonstrated by Doppler ultrasound in upper limb after axillary dissection surgery for the treatment of breast cancer Carolina Nascimben MatheusElaine Caldeira de Oliveira Guirro Clinical trial 29 March 2011 Pages: 697 - 704
A single-center, prospective and randomized controlled study: Can the prophylactic use of lamivudine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy? Meijun LongWeijuan JiaErwei Song Clinical Trial 29 March 2011 Pages: 705 - 712
Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes G. CancelloP. MaisonneuveM. Colleoni Clinical trial 31 March 2011 Pages: 713 - 720
Socioeconomic differences in survival among breast cancer patients in the Netherlands not explained by tumor size E. BastiaannetA. J. M. de CraenG. J. Liefers Epidemiology 13 November 2010 Pages: 721 - 727
Disparities in breast cancer characteristics and outcomes by race/ethnicity Siew Loon OoiMaria Elena MartinezChristopher I. Li Epidemiology 07 October 2010 Pages: 729 - 738
Economic evaluation of the 21-gene signature (Oncotype DX®) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03) Masahide KondoShu-Ling HoshiMasakazu Toi Epidemiology 17 November 2010 Pages: 739 - 749
CAG repeat length polymorphism in the androgen receptor gene and breast cancer risk: data on Indian women and survey from the world Singh RajenderAmirtharaj FrancisKumarasamy Thangaraj Epidemiology 24 November 2010 Pages: 751 - 760
Variation in genes coding for AMP-activated protein kinase (AMPK) and breast cancer risk in the European Prospective Investigation on Cancer (EPIC) Daniele CampaRainer ClausRudolf Kaaks Epidemiology 30 November 2010 Pages: 761 - 767
A variant affecting miRNAs binding in the circadian gene Neuronal PAS domain protein 2 (NPAS2) is not associated with breast cancer risk Furu WangZhibin HuHongbing Shen Epidemiology 08 December 2010 Pages: 769 - 775
Joint effect of peroxisome proliferator-activated receptor γ genetic polymorphisms and estrogen-related risk factors on breast cancer risk: results from a case–control study in Taiwan Mei-Hsuan WuChi-Hong ChuChien-An Sun Epidemiology 08 December 2010 Pages: 777 - 784
IGFBP1 and IGFBP3 polymorphisms predict circulating IGFBP-3 levels among women from high-risk breast cancer families Ann H. RosendahlMaria HietalaHelena Jernström Epidemiology 08 December 2010 Pages: 785 - 794
Two functional variations in 5′-UTR of hoGG1 gene associated with the risk of breast cancer in Chinese Xiaoxiang ChenJingmei WangYaping Wang Epidemiology 14 December 2010 Pages: 795 - 803
Ability to predict breast cancer in Asian women using a polygenic susceptibility model Mikael HartmanChen SuoKee Seng Chia Epidemiology 14 December 2010 Pages: 805 - 812
Current evidence on the relationship between four polymorphisms in the matrix metalloproteinases (MMP) gene and breast cancer risk: a meta-analysis Ping ZhouLiang-Feng DuChun Zhang Epidemiology 15 December 2010 Pages: 813 - 818
Risk of contralateral breast cancer associated with common variants in BRCA1 and BRCA2: potential modifying effect of BRCA1/BRCA2 mutation carrier status Jane C. FigueiredoJennifer D. BrooksJonine L. Bernstein Epidemiology 15 December 2010 Pages: 819 - 829
EMSY and CCND1 amplification in familial breast cancer: from the Ontario site of the Breast Cancer Family Registry Anita L. BaneAnna Marie MulliganIrene L. Andrulis Brief Report 15 February 2011 Pages: 831 - 839
Complete response in HER2+ leptomeningeal carcinomatosis from breast cancer with intrathecal trastuzumab Mafalda OliveiraSofia BragaJoão Oliveira Brief Report 03 March 2011 Pages: 841 - 844
The h index and the identification of global benchmarks for breast cancer research output N. A. HealyR. W. GlynnK. J. Sweeney Brief Report 12 March 2011 Pages: 845 - 851
BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer Michelle W. WongCecilia NordforsRodney J. Scott Brief Report 16 March 2011 Pages: 853 - 859
PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy Pawel DomagalaTomasz HuzarskiWenancjusz Domagala Brief Report 17 March 2011 Pages: 861 - 869
Germline mutational analysis of the C19orf62 gene in African-American women with breast cancer Yonglan ZhengJing ZhangDezheng Huo Brief Report 24 March 2011 Pages: 871 - 877